Milvexian is a pharmaceutical raw material under investigation for its potential as a factor XIa inhibitor. It is currently being evaluated in a clinical trial for the prevention of stroke in patients receiving aspirin and clopidogrel.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1802425-99-5
Filgotinib maleate
pharmaceutical raw material
Clazosentan
pharmaceutical raw material
(1S,3S)-Solifenacin Hydrochloride
pharmaceutical raw material
CT7001 hydrochloride
pharmaceutical raw material
(9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
FSWFYCYPTDLKON-CMJOXMDJSA-N
C[C@@H]1CCC[C@@H](C2=NC=CC(=C2)C3=C(C=NN3C(F)F)NC1=O)N4C=NC(=CC4=O)C5=C(C=CC(=C5)Cl)N6C=C(N=N6)Cl